Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Darya-Varia Laboratoria TbkISX:DVLA +0.63%66 ROC (Joel Greenblatt) % is 20.16% as of Jun. 2026, which is 13% below its 10-year median of 23.30. GuruFocus rates ISX:DVLA with a GF Score™ of 66/100 and a GF Value™ of Rp1,860.92 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 982 Drug Manufacturers companies, PT Darya-Varia Laboratoria Tbk ranks better than 60.59% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. PT Darya-Varia Laboratoria Tbk's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 20.16%.
The historical rank and industry rank for PT Darya-Varia Laboratoria Tbk's ROC (Joel Greenblatt) % or its related term are showing as below:
ISX:DVLA'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 17.5 Med: 23.3 Max: 34.35
Current: 17.5
During the past 13 years, PT Darya-Varia Laboratoria Tbk's highest ROC (Joel Greenblatt) % was 34.35%. The lowest was 17.50%. And the median was 23.30%.
ISX:DVLA's ROC (Joel Greenblatt) % is ranked better than 60.59% of 982
companies
in the Drug Manufacturers industry
Industry Median: 11.28
vs ISX:DVLA: 17.50
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ISX:DVLA vs ZTS, UTHR, VTRS: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PT Darya-Varia Laboratoria Tbk's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Darya-Varia Laboratoria Tbk ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PT Darya-Varia Laboratoria Tbk's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where PT Darya-Varia Laboratoria Tbk's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 20.16% mean?
PT Darya-Varia Laboratoria Tbk (ISX:DVLA) has a ROC (Joel Greenblatt) % of 20.16% as of Jun. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on PT Darya-Varia Laboratoria Tbk and its competitors. This is 13% below median its historical median of 23.30. Over the past decade, PT Darya-Varia Laboratoria Tbk's ROC (Joel Greenblatt) % has ranged from 17.50 to 34.35. According to the industry distribution chart, PT Darya-Varia Laboratoria Tbk ranks #387 out of 982 companies in the Drug Manufacturers industry, placing it in the top 39.4%.
Is PT Darya-Varia Laboratoria Tbk's ROC (Joel Greenblatt) % too high?
PT Darya-Varia Laboratoria Tbk's current ROC (Joel Greenblatt) % of 20.16% is 13% below median its 10-year median of 23.30. Over the past 10 years, this metric has ranged from a low of 17.50 to a high of 34.35. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 11.28. PT Darya-Varia Laboratoria Tbk's value of 20.16% is 78.7% above this industry median. Based on the distribution chart, PT Darya-Varia Laboratoria Tbk ranks #387 out of 982 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, PT Darya-Varia Laboratoria Tbk has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Darya-Varia Laboratoria Tbk's ROC (Joel Greenblatt) % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PT Darya-Varia Laboratoria Tbk ranks #387 out of 982 companies for ROC (Joel Greenblatt) %. This puts PT Darya-Varia Laboratoria Tbk in the upper half of its industry. The industry median ROC (Joel Greenblatt) % is 11.28. PT Darya-Varia Laboratoria Tbk's value of 20.16% is 78.7% above this benchmark. Historically, PT Darya-Varia Laboratoria Tbk's own ROC (Joel Greenblatt) % has ranged from 17.50 to 34.35 over the past decade. While the company's 10-year median is 23.30 vs. the industry median of 11.28, PT Darya-Varia Laboratoria Tbk has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.28, based on 982 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Darya-Varia Laboratoria Tbk's current ROC (Joel Greenblatt) % of 20.16% is 78.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on PT Darya-Varia Laboratoria Tbk and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Darya-Varia Laboratoria Tbk's current ROC (Joel Greenblatt) % is 20.16%, which is 13% below median its own 10-year median of 23.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Darya-Varia Laboratoria Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Darya-Varia Laboratoria Tbk (ISX:DVLA) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp1,860.92, compared to a current price of Rp1,590.00 — trading 14.6% below its estimated fair value. The current ROC (Joel Greenblatt) % is 20.16%, which is 13% below median its 10-year median of 23.30 and 78.7% above the Drug Manufacturers industry median of 11.28. PT Darya-Varia Laboratoria Tbk's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For PT Darya-Varia Laboratoria Tbk (ISX:DVLA), the current ROC (Joel Greenblatt) % is 20.16% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Darya-Varia Laboratoria Tbk (ISX:DVLA) Overvalued in 2026?
Based on GuruFocus' analysis, PT Darya-Varia Laboratoria Tbk stock appears to be undervalued.
The current stock price of Rp1,590.00 is trading 14.6% below its estimated GF Value™ of Rp1,860.92.
GuruFocus considers PT Darya-Varia Laboratoria Tbk to be Modestly Undervalued.
Key valuation signals for ISX:DVLA:
ROC (Joel Greenblatt) %: 20.16% (13% below median its 10-year median of 23.30)
GF Value™: Rp1,860.92 vs. price of Rp1,590.00 (14.6% below fair value)
Industry Position: 78.7% above the Drug Manufacturers median (#387 of 982)
No single metric tells the full story. See the ISX:DVLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Darya-Varia Laboratoria Tbk (Darya-Varia) is operating in the pharmaceutical industry. It is engaged in the manufacture and trade of pharmaceutical products, human, traditional medicines, pharmaceutical materials, raw materials for traditional medicines, inorganic base chemicals, organic base chemicals, equipment for surgery, medical and dental care, and equipment, orthopedic equipment, prosthetic, eyeglasses, laboratory and health equipment from glass, cosmetics, wholesaler of pharmaceutical, traditional medicine, chemical base materials, laboratory testing services, periodic inspection services, and many more activities. Its business segments include: prescription drugs; consumer health products, which derives key revenue; export and toll manufacturing services; and services.
66GF Score
Get the complete analysis for ISX:DVLA
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:DVLA has been successfully added to your 
